ARTICLE | Discovery & Translation

Voyager’s journey to identify a new shuttle for bringing gene therapies into the brain

Biotech identifies ALPL as a cross-species cell surface receptor mediating BBB crossing of AAV capsid family

May 15, 2024 10:54 PM UTC
Updated on May 17, 2024 at 5:35 PM UTC

Voyager has taken two steps toward safer and more effective systemic delivery of new CNS gene therapies. First, the company has found capsids that cross the blood-brain barrier while simultaneously de-targeting the liver; and second, it’s worked backwards to identify the cell surface receptor used by the capsids for brain entry.

Voyager Therapeutics Inc. (NASDAQ:VYGR) reported at this year’s American Society of Gene & Cell Therapy (ASGCT) annual meeting its method of finding a family of capsids that cross the blood-brain barrier (BBB) and how it identified the receptor — ALPL — that the capsids use to do so...